natgillin/translations-raw huggingface dataset:
In the relapsed/refractory study, the median progression-free survival (primary endpoint) was 30.6 months in the R-FC group and 20.6 months in the FC group (p=0.0002, log--rank test). 
FC in 20,6 meseca v skupini FC (p = 0,0002, test log-rang).
Neutropenia can occur several months after the administration of MabThera (see section 4.4). 
MabThera (glejte poglavje 4.4).
Methotrexate (MTX) naïve populations with rheumatoid arthritis The use of MabThera is not recommended in MTX-naïve patients since a favourable benefit risk relationship has not been established. 
Uporaba zdravila MabThera pri bolnikih, ki še niso prejemali metotreksata, ni priporočljiva, ker ni bilo dokazano ugodno razmerje med koristjo in tveganji.
• flushing or redness of the skin 
· trzanje ali tresenje mišic,
EFS - Event Free Survival TTP - Time to progression or death PFS - Progression-Free Survival TTF - Time to Treatment Failure OS rates - survival rates at the time of the analyses 
ORR: celokupni odgovor (Overall Response Rate) CRR: popolni odgovor (Complete Response Rate) PFS: preživetje brez napredovanja bolezni (Progression-Free Survival) (delež z dogodkom, napredovanjem/ponovitvijo bolezni ali smrtjo iz katerega koli vzroka)
Initial treatment, bulky disease, weekly for 4 doses In pooled data from three trials, 39 patients with relapsed or chemoresistant, bulky disease (single lesion ≥ 10 cm in diameter), low grade or follicular B cell NHL received 375 mg/m2 of MabThera as intravenous infusion weekly for four doses. 
Združeni podatki treh preskušanj navajajo, da je 39 bolnikov, pri katerih se je nizko maligni ali folikularni B-celični ne-Hodgkinov limfom ponovil ali pa so bili bolniki neodzivni na kemoterapijo in so imeli obsežno bolezen (ena lezija ³ 10 cm v premeru), prejelo 4 odmerke po 375 mg/m2 zdravila
• indigestion 
· nespečnost,
The safety of immunisation with live viral vaccines, following MabThera therapy has not been studied for NHL patients and vaccination with live virus vaccines is not recommended. 
NHL niso proučevali in cepljenje z živimi virusnimi cepivi ni priporočljivo.
After a median observation time of 31 months for patients randomised to the induction phase, R-CHOP significantly improved the outcome of patients with relapsed/refractory follicular lymphoma when compared to CHOP (see Table 5). 
mesečnega opazovanja izid zdravljenja pomembno izboljšal v primerjavi s skupino CHOP (glejte preglednico 5).
Clinical experience of MabThera concentrate for solution for infusion in CLL 
Klinične izkušnje s koncentratom za raztopino za infundiranje zdravila MabThera pri kronični limfocitni anemiji
Severe infections were reported in about 4% of patients treated with MabThera monotherapy. 
Pri 4 % bolnikov, ki so prejemali zdravilo MabThera kot samostojno zdravljenje, so opazili hude okužbe.
Do not breast-feed while you are being treated with MabThera. 
Med zdravljenjem z zdravilom MabThera ne smete dojiti.
When rituximab sticks to the surface of this cell, the cell dies. 
Veže se na površino vrste belih krvnih celic, limfocitov B. Ko se rituksimab veže na površino teh celic, povzroči njihovo smrt.
See Section 4.2 for information on paediatric use. 
MabThera za vse podskupine pediatrične populacije z avtoimunskim artritisom (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Musculoskelet al, connective tissue and bone disorders hypertonia, myalgia, arthralgia, back pain, neck pain, pain 
Bolezni mišično skeletnega sistema in vezivnega tkiva hipertonija, mialgija, artralgija,
There are no adequate and well-controlled data from studies in pregnant women, however transient B-cell depletion and lymphocytopenia have been reported in some infants born to mothers exposed to MabThera during pregnancy. 
Pri nekaterih dojenčkih, katerih matere so med nosečnostjo prejemale zdravilo MabThera, pa so poročali o prehodnem zmanjšanju števila celic B in limfocitopeniji.
• Infections such as pneumonia (bacterial) 
resna virusna okužba2, pnevmocisto za (Pneumocys tis jirovecii)
In the majority of these cases, MabThera was administered with chemotherapy. 
MabThera uporabili skupaj s kemoterapijo.
Hypogammaglobulinaemia (IgA, IgG or IgM below the lower limit of normal) has been observed in granulomatosis with polyangiitis and microscopic polyangiitis patients treated with MabThera. 
Pri bolnikih z granulomatozo s poliangiitisom ali mikroskopskim poliangiitisom, ki so prejemali zdravilo MabThera, so opažali hipogamaglobulinemijo (IgA, IgG ali IgM pod spodnjo mejo normale).
• coughing or shortness of breath 
· odpoved dihanja,
MARKETING AUTHORISATION NUMBER(S) EU/1/98/067/002 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/98/067/002
This medicine may make you more likely to get infections. 
Ker prejemate zdravilo MabThera, je večja verjetnost, da dobite okužbo.
Nervous system disorders Dizziness 
Bolezni živčevja glavobol omotica
You will always be given MabThera as a drip (intra-venous infusion). 
Zdravilo MabThera boste dobili v intravenski infuziji.
In a multi-centre, single-arm trial, 58 patients with relapsed or chemoresistant low grade or follicular B cell NHL, who had achieved an objective clinical response to a prior course of MabThera, were re-treated with 375 mg/m2 of MabThera as intravenous infusion weekly for four doses. 
Ponovno zdravljenje, 4 odmerki, enkrat na teden V multicentričnem preskušanju brez primerjalne skupine je 58 bolnikov, pri katerih se je nizko maligni ali folikularni B-celični ne-Hodgkinov limfom ponovil ali pa so bili bolniki neodzivni na kemoterapijo ter so dosegli objektivni klinični odgovor na predhodno zdravljenje z zdravilom
MARKETING AUTHORISATION NUMBER(S) EU/1/98/067/004 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/98/067/004
2 What you need to know before you are given MabThera 
Na tej kartici je opisano: · Kaj morate vedeti, preden prejmete zdravilo MabThera
The complete response rate after cycle 8 was 76.2% in the R-CHOP group and 62.4% in the CHOP group (p=0.0028). 
Pri 24 mesecih je bila ocena celokupnega preživetja v skupini R-CHOP 68,2 %, v skupini CHOP pa 57,4 %.
A two-stage phase Ib trial to investigate the pharmacokinetics, safety and tolerability of MabThera subcutaneous formulation in patients with follicular lymphoma (FL) as part of maintenance treatment. 
Preskušanje BP22333 (SparkThera) Pri bolnikih s folikularnimi limfomi so kot del vzdrževalnega zdravljenja izvedli dvostopenjsko preskušanje faze Ib za proučitev farmakokinetike, varnosti in prenašanja podkožne oblike zdravila
Subcutaneous injections: 
glivične okužbe,
Following induction of remission with MabThera, maintenance treatment should be initiated no sooner than 16 weeks after the last MabThera infusion. 
Po indukciji remisije z zdravilom MabThera se vzdrževalnega zdravljenja ne sme začeti prej kot
CHOP (R-CHOP). 
zdravila MabThera in sheme CHOP (R-CHOP).
The incidence of IRR decreased with subsequent courses (see section 4.8). 
in prehodne (glejte poglavje 4.8).
MARKETING AUTHORISATION NUMBER(S) EU/1/98/067/001 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/98/067/001
Dyspepsia, diarrhoea, gastro-oesophageal reflux, mouth ulceration, upper abdominal pain 
Bolezni prebavil dispepsija, diareja, gastroezofagealni refluks, razjede v ustih,
heart failure4 
odpoved dihal4
Number of Subjects with Major Relapse 
ODGOVOREN ZA SPROŠČANJE SERIJ
MabThera is a clear, colourless solution, supplied as a concentrate for solution for infusion. 
Zdravilo MabThera je bistra, brezbarvna raztopina.
CRR - Complete Response Rate 
CRRa ocena
• severe skin problems causing blisters that can be life-threatening. 
· okvara črevesne stene (predrtje), · hude težave s kožo, ki povzročijo mehurje in so lahko smrtno nevarne.
patients. 
stopnje).
infusion and the mean terminal half-life was 32 days (range, 14 - 62 days). 
Povprečni končni razpolovni čas izločanja je bil 15 do 16 dni za 2
and 6 
Pri 24
MabThera is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV). 
Zdravilo MabThera je indicirano za zdravljenje bolnikov z zmernim do hudim navadnim pemfigusom.
Premedication with glucocorticoids should be considered if MabThera is not given in combination with glucocorticoid-containing chemotherapy. 
Če zdravilo MabThera ni uporabljeno v kombinaciji s kemoterapijo, ki vključuje glukokortikoid, je treba razmisliti o premedikaciji z glukokortikoidi.
At 24 months, estimates for overall survival were 68.2% in the R-CHOP arm compared to 57.4% in the CHOP arm. A subsequent analysis of the duration of overall survival, carried out with a median follow-up duration of 60 months, confirmed the benefit of R-CHOP over CHOP treatment (p=0.0071), representing a risk reduction of 
Nadaljnja analiza trajanja celokupnega preživetja, ki so jo izvedli po mediani časa sledenja 60 mesecev, je potrdila prednost zdravljenja z R-CHOP pred CHOP
• eating disorders, not eating enough, leading to weight loss 
zaprtost, težave z želodcem · motnje hranjenja, nezadostno uživanje hrane, kar povzroči hujšanje
Baseline CD19-positive cell counts and size of measurable tumour lesions contributed to some of the variability in CL2 of MabThera in data from 161 patients given 375 mg/m2 as an intravenous infusion for 4 
K variabilnosti Cl2 zdravila MabThera pri 161 bolnikih, ki so v štirih tednih enkrat na teden dobili 375 mg/m2 zdravila
**: only applicable to patients achieving a CR; 
NR: ni doseženo; a: velja le za bolnike, ki so dosegli CR (popolni odgovor).
Premedication consisting of an analgesic/antipyretic and an antihistamine should always be administered before each dose of MabThera subcutaneous formulation. 
Pred vsakim odmerkom podkožne oblike zdravila MabThera mora bolnik vedno dobiti premedikacijo, ki obsega analgetik/antipiretik in antihistaminik.
MARKETING AUTHORISATION NUMBER(S) EU/1/98/067/003 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/98/067/003
Severe IRRs with fatal outcome have been reported in rheumatoid arthritis patients in the post-marketing setting. 
V obdobju trženja so pri bolnikih z revmatoidnim artritisom poročali o resnih, z infuzijo povezanih reakcijah, ki so se končale s smrtjo.
• heart beating faster than normal 
· bolečina v trebuhu, · bolečina v mišicah, · hitrejše bitje srca kot običajno.
cells/μL after two weekly infusions of rituximab 375 mg/m2, and remained at that level in most patients up to the 6 month timepoint. 
Pri bolnikih z granulomatozo s poliangiitisom in mikroskopskim poliangiitisom se je število perifernih celic B zmanjšalo na < 10 celic/µl po dveh infundiranjih 375 mg/m2 rituksimaba (po enem na teden) in je na tej ravni ostalo do 6 mesecev.
MabThera subcutaneous formulation at a fixed dose of 1400 mg was administered for 6 cycles subcutaneously during induction at 3-weekly intervals, following the first cycle of MabThera intravenous formulation, in previously untreated FL patients in combination with chemotherapy. 
Predhodno še nezdravljenim bolnikom s folikularnimi limfomi so (v kombinaciji s kemoterapijo) po opravljenem prvem ciklu zdravljenja z intravensko obliko zdravila MabThera dajali podkožno obliko zdravila v fiksnem odmerku 1400 mg, in sicer 6 ciklov podkožno med indukcijskim zdravljenjem v 3tedenskih presledkih.
• Abnormal sensations of the skin, such as numbness, tingling, pricking or burning, sciatica, 
· neobičajni občutki na koži - na primer omrtvičenost, mravljinčenje, zbadanje, pekoč občutek, občutek gomazenja na koži, slabše zaznavanje dotika,
Pneumocystis jirovecii 
Geometrična sredina AUCτ
A total of 6/34 (18%) of MabThera treated patients from the maintenance therapy clinical trial developed ADA. 
V kliničnem preskušanju vzdrževalnega zdravljenja so se ADA pojavila pri skupno 6 od 34 (18 %) bolnikov, zdravljenih z zdravilom MabThera.
MabThera at a fixed dose of 1600 mg was administered for 5 cycles subcutaneously at 4-weekly intervals, following the first cycle of MabThera intravenous formulation, in previously untreated CLL patients in combination with chemotherapy (fludarabine and cyclophosphamide (FC). 
Bolnikom s KLL, ki še niso bili zdravljeni, so v kombinaciji s kemoterapijo (fludarabinom in ciklofosfamidom (FC)) po opravljenem prvem ciklu zdravljenja z intravensko obliko zdravila MabThera dajali podkožno obliko zdravila v fiksnem odmerku 1600 mg, in sicer 5 ciklov podkožno v 4-tedenskih presledkih.
OS rates, 
neješčnost,
METHOD AND ROUTE(S) OF ADMINISTRATION For subcutaneous use only 
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Very rare cases of PML have been reported during post-marketing use of the MabThera intravenous formulation in NHL (see section 4.8). 
opisani zelo redki primeri PML (glejte poglavje 4.8).
They were characterized by pulmonary events and in some cases included rapid tumour lysis and features of tumour lysis syndrome in addition to fever, chills, rigors, hypotension, urticaria, angioedema and other symptoms (see section 4.8). 
Značilni zanje so bili pljučni dogodki in v nekaterih primerih hiter razpad tumorja z značilnostmi sindroma razpada tumorja, poleg zvišane telesne temperature, mrzlice,
Log-Rank p value 
Vrednost p v testu log rang
This includes rheumatoid arthritis and off-label autoimmune diseases, including Systemic Lupus Erythematosus (SLE) and vasculitis. 
Pri uporabi zdravila MabThera za zdravljenje revmatoidnega artritisa in avtoimunskih bolezni, ki vključujejo sistemski eritematozni lupus (SLE) in vaskulitis, so poročali o zelo redkih primerih smrtne progresivne multifokalne levkoencefalopatije (PML).
Diluted medicinal product 
UPORABO ZDRAVILA
MabThera maintenance treatment consisted of a single infusion of MabThera at 375 mg/m2 body surface area given every 2 months until disease progression or for a maximum period of two years. 
V okviru vzdrževalnega zdravljenja so bolniki prejeli eno infuzijo zdravila MabThera v odmerku 375 mg/m2 telesne površine vsaka 2
Look out for the following possible signs of infection: 
Bodite pozorni na naslednje znake okužbe: · zvišana telesna temperatura ali neprestano kašljanje,
Further information on Taxotere can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/taxotere. 
Nadaljnje informacije za zdravilo Taxotere so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/taxotere.
The European Medicines Agency decided that Taxotere's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Taxotere večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of Taxotere? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Taxotere?
Taxotere received a marketing authorisation valid throughout the EU on 27 November 1995. 
Za zdravilo Taxotere je bilo 27. novembra 1995 izdano dovoljenje za promet, veljavno po vsej EU.
Other information about Taxotere 
Druge informacije o zdravilu Taxotere
As for all medicines, data on the use of Taxotere are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Taxotere stalno spremljajo.
What benefits of Taxotere have been shown in studies? 
Kakšne koristi zdravila Taxotere so se pokazale v študijah?
What is Taxotere and what is it used for? 
Kaj je zdravilo Taxotere in za kaj se uporablja?
Why is Taxotere authorised in the EU? 
Zakaj je bilo zdravilo Taxotere odobreno v EU?
With the skeleton still in place, the cells cannot divide and they eventually die. 
Če je ogrodje prisotno, se celice ne morejo deliti in sčasoma odmrejo.
Side effects reported with Taxotere are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Taxotere, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Taxotere have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Taxotere upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What are the risks associated with Taxotere? 
Kakšna tveganja so povezana z zdravilom Taxotere?
Adding Taxotere to other anticancer treatments was effective in all five types of cancer. 
Dodajanje zdravila Taxotere drugim zdravilom za zdravljenje raka je bilo učinkovito pri vseh petih vrstah raka.
Taxotere can be used on its own after other treatments have failed. 
Zdravilo Taxotere se lahko uporablja samostojno po neuspešnih drugih oblikah zdravljenja.
Taxotere has been studied in over 4,000 breast-cancer patients, around 2,000 non-small-cell-lungcancer patients, around 2,700 prostate cancer patients, 457 gastric adenocarcinoma patients and 897 head- and neck-cancer patients. 
Zdravilo Taxotere so proučevali pri več kot 4 000 bolnicah z rakom dojke, približno 2 000 bolnikih z nedrobnoceličnim pljučnim rakom, približno 2 700 bolnikih z rakom prostate, 457 bolnikih z želodčnim adenokarcinomom in 897 bolnikih z rakom glave in vratu.
Taxotere must not be used in patients who have a neutrophil count of less than 1,500 cells/mm3 or who have severe problems with their liver. 
Zdravilo Taxotere se ne sme uporabljati pri bolnikih, pri katerih je število nevtrofilcev manjše od 1 500 celic/mm3, ali pri bolnikih s hudimi težavami z jetri.
• prostate cancer, when the cancer has spread to other parts of the body (metastatic). 
• raka prostate, kadar se je rak razširil na druge dele telesa (je metastatski).
The dose of Taxotere may need to be reduced, or treatment interrupted or discontinued, if the patient develops certain side effects. 
Odmerek zdravila Taxotere bo morda treba zmanjšati ali prekiniti oziroma ukiniti zdravljenje, če se pri bolniku pojavijo določeni neželeni učinki.
An overview of Taxotere and why it is authorised in the EU 
Pregled zdravila Taxotere in zakaj je odobreno v EU
Taxotere is used with cisplatin and fluorouracil. 
Zdravilo Taxotere se uporablja s cisplatinom in fluoroacilom.
Docetaxel blocks the ability of cells to break down the internal ‘skeleton' that allows them to divide. 
Docetaksel zavira sposobnost celic, da uničijo notranje „ogrodje“, ki jim omogoča deljenje in razmnoževanje.
In most of these studies, Taxotere was combined with other cancer treatments and compared either with the medicines it is used in combination with or with a combination of different treatments. 
V večini teh študij je bilo zdravilo Taxotere uporabljeno v kombinaciji z drugim zdravilom za zdravljenje raka in primerjano bodisi z zdravili, v kombinaciji s katerimi je bilo uporabljeno, bodisi s kombinacijami različnih zdravljenj.
Taxotere is a cancer medicine used to treat the following types of cancer: 
Taxotere je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje naslednjih vrst raka:
For more information about using Taxotere, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Taxotere glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
• non-small cell lung cancer. 
• nedrobnoceličnega pljučnega raka.
An anti-inflammatory medicine such as dexamethasone should also be given to the patient, starting on the day before the Taxotere infusion. 
Bolniku je treba dati tudi protivnetno zdravilo, kot je na primer deksametazon, in sicer dan pred infuzijo zdravila Taxotere.
The most common side effects with Taxotere (seen in more than 1 patient in 10) are neutropenia (low levels of neutrophils, white blood cells that fight infection), anaemia (low red blood cell counts), stomatitis (inflammation of the lining of the mouth), diarrhoea, nausea (feeling sick), vomiting, alopecia (hair loss) and asthenia (weakness). 
Najpogostejši neželeni učinki zdravila Taxotere (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) so nevtropenija (nizke vrednosti nevtrofilcev, belih krvnih celic, ki se borijo proti okužbam), anemija (nizko število rdečih krvnih celic), stomatitis (vnetje ustne sluznice), driska, navzeja (siljenje na bruhanje), bruhanje, alopecija (izpadanje las) in astenija (šibkost).
• head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread). 
• lokalno napredovalega raka glave in vratu pri bolnikih (rak je zrastel, vendar se ni razširil).
Because docetaxel works on dividing cells, it also affects affects non-cancer cells such as blood cells, which can cause side effects. 
Docetaksel učinkuje na delitev celic, zato vpliva tudi na nerakave celice, kot so krvne celice, kar lahko povzroči neželene učinke.
The main measures of effectiveness were the number of patients whose cancer responded to treatment, how long the patients lived without their disease getting worse and how long the patients survived. 
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se je rak odzval na zdravljenje, čas do poslabšanja bolezni in čas preživetja.
It can also be used with androgen-deprivation therapy when hormonal treatment still works (hormone-sensitive prostate cancer); 
Lahko se uporablja tudi s terapijo odtegnitve androgenov, kadar hormonsko zdravljenje še vedno deluje (rak prostate, občutljiv na hormone);
The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated and the patient's weight and height. 
Odmerek, trajanje zdravljenja in njegova souporaba z drugimi zdravili so odvisni od vrste raka, ki se zdravi, ter bolnikove višine in telesne mase.
These side effects may be more severe when Taxotere is used with other cancer medicines. 
Ti neželeni učinki so lahko resnejši, kadar se zdravilo Taxotere uporablja z drugimi zdravili za zdravljenje raka.
When used on its own, Taxotere was at least as effective as and sometimes more effective than the comparator medicines in breast cancer, and more effective than best supportive care (any medicines or treatment to help patients, but not other cancer medicines) in lung cancer. 
Kadar se je zdravilo Taxotere uporabljalo samostojno, je bilo pri raku dojke enako ali včasih bolj učinkovito kot primerjalna zdravila, pri pljučnem raku pa učinkovitejše kot najboljša podporna nega (katera koli zdravila ali zdravljenja, ki bolnikom pomagajo, a niso druga zdravila za zdravljenje raka).
• gastric adenocarcinoma (a stomach cancer) that has spread in patients who have not received any treatment for their cancer. 
• gastričnega adenokarcinoma (vrste želodčnega raka), ki se je razširil pri bolnikih, ki se zaradi raka še niso zdravili.
Taxotere is used with prednisone or prednisolone (anti-inflammatory medicines) when the cancer cannot be treated by greatly reducing the body's production of testosterone (castration-resistant prostate cancer). 
Zdravilo Taxotere se uporablja s prednizonom ali prednizolonom (protivnetnima zdraviloma), kadar raka ni mogoče zdraviti z velikim zmanjšanjem proizvodnje testosterona (na kastracijo odporen rak prostate).
Taxotere is given as a 1-hour infusion (drip) into a vein every 3 weeks. 
Zdravilo Taxotere se daje z enournim infundiranjem (kapalno infuzijo) v veno vsake tri tedne.
Taxotere is used with cisplatin and fluorouracil (other cancer medicines); 
Zdravilo Taxotere se uporablja s cisplatinom in fluoroacilom (drugima zdraviloma za zdravljenje raka);
It can also be used with other cancer medicines (doxorubicin, cyclophosphamide, trastuzumab or capecitabine) in patients who have not yet received any treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated; 
Prav tako se lahko uporablja sočasno z drugimi zdravili za zdravljenje raka (doksorubicinom, ciklofosfamidom, trastuzumabom ali kapecitabinom) pri bolnikih, ki se še niso zdravili proti raku ali pri katerih so bile druge oblike zdravljenja neuspešne, kar je odvisno od vrste in stadija raka dojke, ki se zdravi;
The active substance in Taxotere, docetaxel, belongs to the group of cancer medicines known as taxanes. 
Učinkovina v zdravilu Taxotere, docetaksel, spada v skupino zdravil za zdravljenje raka, imenovanih taksani.